Tenaya therapeutics reports fourth quarter and full year 2023 financial results and provides business update

Initial data from ongoing mypeak™-1 phase 1b of tn-201 for mybpc3-associated hcm expected in second half of 2024 on track to dose first patient in ridge™-1phase 1b clinical trial of tn-401 for pkp2-associated arvc in second half 2024 $47 million net proceeds from recent financing extends cash runway into second half of 2025 south san francisco, calif., march 18, 2024 (globe newswire) -- tenaya therapeutics, inc. (nasdaq: tnya), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update.
TNYA Ratings Summary
TNYA Quant Ranking